We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Comparison of overall survival of lisocabtagene maraleucel (liso‐cel) versus standard of care (SOC) adjusting for crossover in second‐line (2L) R/R large B‐cell lymphoma.
- Authors
Morschhauser, F.; Ghesquieres, H.; Kamdar, M.; Liu, F. F.; Chandler, C.; Crotta, A.; Klijn, S. L.; Elsada, A.; Previtali, A.; Chaillol, I.; Proskorovsky, I.; Schmitz, N.; Gisselbrecht, C.; Abramson, J. S.
- Abstract
B Introduction: b TRANSFORM (NCT03575351) is a multinational, phase 3 study that compared efficacy and safety of liso-cel versus SOC, including overall survival (OS) as a key secondary endpoint, as a 2L treatment for patients (pt) with relapsed/refractory (R/R) large B-cell lymphoma who were eligible for transplant. Comparison of overall survival of lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) adjusting for crossover in second-line (2L) R/R large B-cell lymphoma Additionally, as real-world use of chimeric antigen receptor (CAR) T cell therapies in 3L may be less common compared with TRANSFORM, the ITT analysis may provide a conservative estimate of the treatment effect for liso-cel versus SOC on OS.
- Subjects
OVERALL survival; CHIMERIC antigen receptors; LYMPHOMAS
- Publication
Hematological Oncology, 2023, Vol 41, p451
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3164_332